William Blair Initiates Coverage on Faeth Therapeutics With Outperform Rating
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to S&P Biotechnology Select Industry Index CI Sep. 20 Faeth Therapeutics, Inc.
Model output · Signal date 2026-10-16
Faeth Therapeutics, Inc. (FTH) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Rating · 90D
Alpha
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
Middle 30%
of 5171 stocks scored
Rank correlation · 90D
7.0%
Spearman, 357 dates
Market Cap
$486M
small-cap · #60 of 60 peers
Summary
Faeth Therapeutics, Inc. (FTH) stock forecast summary
On Oct. 16, 2026, FTH is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
Faeth Therapeutics, Inc. is a small-cap company with a market capitalization of $486M. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For FTH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 7.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, FTH included.
Follow FTH freePrice
FTH price chart and AI forecast
Cross-section · 2026-10-16
How FTH ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-06-30
Faeth Therapeutics, Inc. (FTH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | FTH | Rank |
|---|---|---|
| Market Cap | $486M | 60/60 |
| P/B Ratio | 2.81x | 38/42 |
| EPS | $-141.70 | – |
| Book Value/Share | $6.69 | – |
| FCF/Share | $-1.31 | – |
Profitability & Margins
| Metric | FTH | Rank |
|---|---|---|
| ROIC | -110.6% | 44/46 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | FTH | Rank |
|---|---|---|
| Current Ratio | 19.69x | 7/59 |
| D/E Ratio | 0.06x | 42/48 |
| Financial Leverage | 1.09x | 40/48 |
| Interest Coverage | -1652.3x | 35/36 |
| Working Capital | $179M | 51/59 |
Cash Flow
| Metric | FTH | Rank |
|---|---|---|
| Operating Cash Flow | -$34M | 39/59 |
| Free Cash Flow | -$34M | 32/50 |
| Capital Spending | -$10K | 1/50 |
Income Statement
| Metric | FTH | Rank |
|---|---|---|
| Operating Income | -$199M | 34/51 |
Dividend & Shareholder Information
| Metric | FTH | Rank |
|---|---|---|
| Shares Outstanding | 26M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $189M | |
| Cash & Short-term Investments | $27M | 14.7% of assets |
| Total Liabilities | $10M | 5.3% of assets |
| Short-term Debt | $7M | 4.1% of assets |
Quarterly Financial Reports
FTH quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Faeth Therapeutics, Inc. (FTH) industry peers
Companies classified under the same SEC industry code as Faeth Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| FTH Faeth Therapeutics, Inc. | ▶ | $486M |
| LLY Eli Lilly & Co | ▶ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▶ | $504.46B |
| MRK Merck & Co., Inc. | ▲ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.37B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▶ | $168.60B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $128.95B |
| BMY Bristol Myers Squibb Co | ▶ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $100.12B |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $81.76B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.45B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.36B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.40B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.88B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.22B |
| GMAB Genmab A/S | ▲ | $23.80B |
| UTHR United Therapeutics Corp | ▶ | $23.23B |
| INSM Insmed Inc | ▶ | $21.02B |
| VTRS Viatris Inc | ▼ | $20.93B |
| ASND Ascendis Pharma A/S | ▲ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▼ | $11.77B |
| SMMT Summit Therapeutics Inc. | ▶ | $11.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.91B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.39B |
| TGTX Tg Therapeutics, Inc. | ▲ | $8.89B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.33B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.06B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▶ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▲ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $5.93B |
| LGND Ligand Pharmaceuticals Inc | ▶ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▶ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.94B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.44B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▶ | $3.83B |
Where FTH sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Faeth Therapeutics, Inc. (FTH) stock news
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to S&P Global BMI Index
Faeth Therapeutics, Inc.(NasdaqCM:FTH) added to S&P Global BMI Index CI Sep. 17 Faeth Therapeutics, Inc. Announces Appointment of Karen Vousden to Board of Directors and Compensation Committee Member, ...
What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." ...
FAQ
Faeth Therapeutics, Inc. (FTH) stock forecast FAQ
What is the Faeth Therapeutics, Inc. (FTH) stock forecast?
On Oct. 16, 2026, FTH is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Faeth Therapeutics, Inc. stock predictions?
For FTH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 7.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 7.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Faeth Therapeutics, Inc. forecasts updated?
Faeth Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Faeth Therapeutics, Inc.'s industry peers?
60 issuers in our coverage, FTH included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.